[
    {
        "pregunta": "1. ¿Qué tratamientos farmacológicos se recomiendan condicionalmente para pacientes adultos con riesgo muy alto de fractura por GIOP?",
        "respuesta": "Para pacientes adultos con riesgo muy alto de fractura por osteoporosis inducida por glucocorticoides (GIOP), se recomiendan condicionalmente tratamientos farmacológicos como bisfosfonatos (por ejemplo, alendronato o risedronato) y denosumab. Estos medicamentos ayudan a aumentar la densidad ósea y reducir el riesgo de fracturas. La elección del tratamiento debe individualizarse según las características del paciente y la tolerancia al medicamento."
    },
    {
        "pregunta": "2. Which osteoporosis medications are strongly recommended for adults ≥40 years with high or very high risk of fracture due to glucocorticoid-induced osteoporosis (GIOP)?",
        "respuesta": "For adults aged 40 years and older with high or very high risk of fracture due to glucocorticoid-induced osteoporosis (GIOP), the medications strongly recommended are **bisphosphonates** (such as alendronate, risedronate, or zoledronic acid) and **denosumab**. These agents have been shown to effectively increase bone mineral density and reduce fracture risk in this population. In some cases, **teriparatide** (a parathyroid hormone analog) may also be considered, especially in very high-risk patients or those who do not respond to or tolerate other treatments."
    },
    {
        "pregunta": "3. ¿Cuál es la dosis mínima de glucocorticoides a partir de la cual se recomienda evaluar el riesgo de osteoporosis inducida por glucocorticoides (GIOP)?",
        "respuesta": "La dosis mínima de glucocorticoides a partir de la cual se recomienda evaluar el riesgo de osteoporosis inducida por glucocorticoides (GIOP) es de 5 mg diarios de prednisona (o su equivalente) durante un período igual o mayor a 3 meses."
    },
    {
        "pregunta": "4. Which bone mineral density (BMD) T-score thresholds correspond to low, moderate, high, and very high fracture risk in glucocorticoid-treated adults?",
        "respuesta": "In glucocorticoid-treated adults, fracture risk is stratified based on BMD T-scores as follows:\n\n- **Low risk:** T-score better than -1.0 (i.e., > -1.0)\n- **Moderate risk:** T-score between -1.0 and -2.4\n- **High risk:** T-score between -2.5 and -2.9\n- **Very high risk:** T-score ≤ -3.0\n\nThese thresholds help guide treatment decisions, considering that glucocorticoid use increases fracture risk even at higher BMD levels compared to the general population."
    },
    {
        "pregunta": "5. For adults ≥40 years at moderate fracture risk receiving glucocorticoid therapy, what osteoporosis treatments are conditionally recommended?",
        "respuesta": "For adults aged 40 years and older at moderate fracture risk who are receiving glucocorticoid therapy, osteoporosis treatments that are conditionally recommended typically include oral bisphosphonates such as alendronate or risedronate. These medications help reduce fracture risk by increasing bone density. The recommendation is conditional because treatment decisions should consider individual patient factors, preferences, and potential risks. Other treatments may be considered based on patient-specific circumstances, but oral bisphosphonates are the primary conditional recommendation in this group."
    },
    {
        "pregunta": "6. What are the major considerations when deciding to use anabolic agents as initial therapy in glucocorticoid-induced osteoporosis?",
        "respuesta": "When considering anabolic agents as initial therapy for glucocorticoid-induced osteoporosis (GIO), major considerations include:\n\n1. **Severity of Bone Loss and Fracture Risk**: Anabolic therapy is typically reserved for patients with very high fracture risk or severe osteoporosis, as it directly stimulates bone formation.\n\n2. **Previous Treatment History**: Patients who have not responded adequately to antiresorptive agents or who have contraindications to them may be candidates for anabolic agents.\n\n3. **Duration and Dose of Glucocorticoid Use**: Long-term or high-dose glucocorticoid therapy increases fracture risk, potentially justifying the use of anabolic therapy.\n\n4. **Safety and Side Effect Profile**: Anabolic agents may have specific risks (e.g., osteosarcoma risk with teriparatide in animal studies), limiting duration of use and patient eligibility.\n\n5. **Cost and Accessibility**: Anabolic therapies are often more expensive and may not be covered by all insurance plans, impacting feasibility.\n\n6. **Patient Factors**: Age, comorbidities, and preferences should be considered, as anabolic agents require daily injections and monitoring.\n\nIn summary, anabolic agents are primarily considered upfront in GIO for patients at very high fracture risk, those intolerant or unresponsive to antiresorptives, and when rapid bone formation is desired."
    },
    {
        "pregunta": "7. ¿Cuáles son las categorías de riesgo de fractura establecidas en la guía para pacientes con osteoporosis inducida por glucocorticoides?",
        "respuesta": "Las categorías de riesgo de fractura establecidas en la guía para pacientes con osteoporosis inducida por glucocorticoides generalmente se clasifican en tres grupos:\n\n1. **Riesgo bajo:** Pacientes que reciben glucocorticoides a dosis bajas o por períodos cortos, sin otros factores de riesgo adicionales y con densidad ósea normal.\n\n2. **Riesgo moderado:** Pacientes con uso prolongado de glucocorticoides (por ejemplo, más de 3 meses), dosis moderadas, o presencia de uno o más factores de riesgo adicionales (edad avanzada, historia previa de fracturas, baja densidad mineral ósea).\n\n3. **Riesgo alto:** Pacientes con dosis altas de glucocorticoides, uso prolongado, antecedentes de fracturas por fragilidad o densidad ósea significativamente disminuida (osteoporosis establecida).\n\nEstas categorías ayudan a decidir la necesidad y el tipo de intervención preventiva o terapéutica."
    },
    {
        "pregunta": "8. What is the role of parathyroid hormone (PTH) or PTH-related protein (PTHrP) agonists in the management of GIOP?",
        "respuesta": "Parathyroid hormone (PTH) and PTH-related protein (PTHrP) agonists, such as teriparatide, play a key role in the management of glucocorticoid-induced osteoporosis (GIOP) by stimulating bone formation. Unlike antiresorptive agents, these anabolic therapies promote new bone growth, increase bone mineral density, and improve bone microarchitecture, helping to counteract the decreased bone formation caused by glucocorticoids. They are particularly useful in patients with severe osteoporosis or those who have failed or cannot tolerate other treatments."
    },
    {
        "pregunta": "9. ¿Qué precauciones se deben tener con la discontinuación del denosumab (DEN) en el tratamiento de GIOP?",
        "respuesta": "Al discontinuar el denosumab en el tratamiento de la osteoporosis inducida por glucocorticoides (GIOP), es fundamental tener precaución debido al riesgo de pérdida rápida de masa ósea y aumento del riesgo de fracturas, especialmente vertebrales. Para minimizar este riesgo, se recomienda iniciar un tratamiento alternativo con bifosfonatos u otro agente antirresortivo inmediatamente después de suspender el denosumab, con el fin de preservar la densidad ósea y prevenir fracturas. Además, se debe realizar un seguimiento estrecho de la densidad mineral ósea y evaluar el riesgo individual del paciente."
    },
    {
        "pregunta": "10. What is the recommended management of osteoporosis therapy in adults who discontinue glucocorticoids and have no new fragility fractures with a current BMD T-score ≥ -2.5?",
        "respuesta": "For adults who discontinue glucocorticoids, have no new fragility fractures, and have a current BMD T-score ≥ -2.5, the recommended management is to consider stopping osteoporosis therapy with close monitoring. If fracture risk remains low and no new fractures occur, therapy may be discontinued, but periodic reassessment with BMD and clinical evaluation is advised to detect any changes in risk."
    },
    {
        "pregunta": "11. When might switching from oral bisphosphonates to intravenous bisphosphonates, denosumab, romosozumab, or PTH/PTHrP be recommended in glucocorticoid-induced osteoporosis?",
        "respuesta": "Switching from oral bisphosphonates to intravenous bisphosphonates, denosumab, romosozumab, or PTH/PTHrP in glucocorticoid-induced osteoporosis may be recommended when patients have contraindications or intolerance to oral bisphosphonates, poor adherence to oral therapy, inadequate response to oral bisphosphonates (e.g., continued bone loss or fractures), or when rapid and potent anti-fracture efficacy is needed."
    },
    {
        "pregunta": "12. How should treatment strategies differ for patients receiving high-dose glucocorticoids (≥30 mg/day for >30 days or cumulative ≥5 g/year)?",
        "respuesta": "For patients receiving high-dose glucocorticoids (≥30 mg/day for >30 days or cumulative ≥5 g/year), treatment strategies should include:\n\n1. **Infection Prophylaxis:** Increased risk of infections necessitates prophylactic measures, such as Pneumocystis jirovecii pneumonia (PJP) prophylaxis with trimethoprim-sulfamethoxazole when appropriate.\n\n2. **Bone Health Management:** Implement bone protection strategies, including calcium and vitamin D supplementation and consideration of bisphosphonates to prevent glucocorticoid-induced osteoporosis.\n\n3. **Metabolic Monitoring:** Regular monitoring and management of blood glucose, blood pressure, and lipid profiles to address glucocorticoid-induced metabolic side effects.\n\n4. **Gastrointestinal Protection:** Use of proton pump inhibitors or H2 blockers for gastroprotection, especially in patients with risk factors for GI bleeding.\n\n5. **Tapering Plan:** Develop a careful glucocorticoid tapering schedule to minimize adrenal insufficiency risk.\n\n6. **Vaccinations:** Ensure up-to-date immunizations before starting therapy, avoiding live vaccines during treatment.\n\nThese strategies aim to mitigate the adverse effects associated with prolonged high-dose glucocorticoid use."
    },
    {
        "pregunta": "13. What fracture risk assessment tools or adjustments are suggested for patients on glucocorticoids?",
        "respuesta": "For patients on glucocorticoids, fracture risk assessment tools such as FRAX (Fracture Risk Assessment Tool) are commonly used, but adjustments are recommended because glucocorticoid use increases fracture risk beyond what FRAX estimates by default. Specifically:\n\n- If the patient is on a **low dose** of glucocorticoids (<7.5 mg prednisone equivalent daily), the fracture risk estimated by FRAX can be **used as is**.\n- If the patient is on a **high dose** of glucocorticoids (≥7.5 mg prednisone equivalent daily), the fracture risk estimated by FRAX should be **adjusted upward**. For example, increase the estimated probability of major osteoporotic fracture by about 15% and hip fracture by about 20%.\n\nAdditionally, some guidelines recommend considering glucocorticoid use as a separate risk factor and, when possible, using glucocorticoid-specific FRAX adjustments or alternative tools that incorporate glucocorticoid dose and duration.\n\nOverall, fracture risk assessment in glucocorticoid-treated patients should consider dose, duration, and clinical context to guide treatment decisions."
    },
    {
        "pregunta": "14. What is the risk associated with discontinuation of denosumab after two or more doses, and what is the recommended follow-up treatment?",
        "respuesta": "Discontinuation of denosumab after two or more doses is associated with a rapid rebound increase in bone resorption, leading to an increased risk of multiple vertebral fractures. To mitigate this risk, it is recommended to follow denosumab discontinuation with alternative antiresorptive therapy, typically a bisphosphonate, to maintain bone density and reduce fracture risk."
    },
    {
        "pregunta": "15. What fracture types are included in the definition of major osteoporotic fractures (MOF) in GIOP?",
        "respuesta": "Major osteoporotic fractures (MOF) in glucocorticoid-induced osteoporosis (GIOP) typically include fractures of the hip, clinical spine (vertebral), forearm (distal radius), and humerus. These fracture sites are considered indicative of significant osteoporosis-related fracture risk."
    },
    {
        "pregunta": "16. How is the FRAX tool adjusted for glucocorticoid use when assessing fracture risk in adults ≥40 years old?",
        "respuesta": "The FRAX tool includes glucocorticoid use as a binary input (yes/no) when assessing fracture risk in adults aged 40 years and older. However, because fracture risk varies with glucocorticoid dose, adjustments to the FRAX output are recommended based on daily glucocorticoid dose:  \n\n- **Low dose (<2.5 mg prednisone equivalent/day):** Decrease the FRAX-estimated fracture probability by about 20%.  \n- **Medium dose (2.5–7.5 mg/day):** Use the FRAX estimate as calculated (no adjustment).  \n- **High dose (>7.5 mg/day):** Increase the FRAX-estimated fracture probability by about 15–20%.  \n\nThis adjustment helps better reflect the actual fracture risk associated with glucocorticoid therapy."
    },
    {
        "pregunta": "17. Why is switching from denosumab to PTH/PTHrP not recommended in glucocorticoid-induced osteoporosis?",
        "respuesta": "Switching from denosumab to PTH/PTHrP in glucocorticoid-induced osteoporosis is not recommended because denosumab suppresses bone resorption, and abrupt discontinuation can lead to a rebound increase in bone turnover and rapid bone loss. Initiating PTH/PTHrP, which stimulates bone formation and resorption, immediately after stopping denosumab may exacerbate this imbalance, increasing the risk of fractures. Therefore, careful management and alternative strategies are preferred to avoid this rebound effect."
    },
    {
        "pregunta": "18. Why should bisphosphonates be avoided in patients with advanced CKD undergoing treatment for glucocorticoid-induced osteoporosis?",
        "respuesta": "Bisphosphonates should be avoided in patients with advanced chronic kidney disease (CKD) because they are primarily cleared by the kidneys, and impaired renal function can lead to drug accumulation and increased risk of toxicity. Additionally, bisphosphonates can potentially worsen renal function and cause adynamic bone disease in CKD patients, making them unsuitable for treating glucocorticoid-induced osteoporosis in this population."
    },
    {
        "pregunta": "19. ¿Qué efectos adversos importantes se asocian con el uso de bisfosfonatos intravenosos, denosumab y romosozumab en el tratamiento de la osteoporosis inducida por glucocorticoides?",
        "respuesta": "Los efectos adversos importantes asociados con el uso de bisfosfonatos intravenosos, denosumab y romosozumab en el tratamiento de la osteoporosis inducida por glucocorticoides son los siguientes:\n\n- **Bisfosfonatos intravenosos:** pueden causar síntomas pseudogripales (fiebre, mialgias), hipocalcemia, nefrotoxicidad y, en casos raros, osteonecrosis de mandíbula y fracturas atípicas de fémur.\n\n- **Denosumab:** se asocia con riesgo de hipocalcemia, infecciones (especialmente de piel y vías respiratorias), osteonecrosis de mandíbula y, también, fracturas atípicas de fémur tras uso prolongado.\n\n- **Romosozumab:** puede aumentar el riesgo cardiovascular (infarto de miocardio, accidente cerebrovascular) en pacientes con antecedentes de enfermedad cardiovascular, además de hipocalcemia y reacciones en el sitio de inyección.\n\nEs importante monitorizar a los pacientes durante el tratamiento para detectar y manejar oportunamente estos efectos adversos."
    },
    {
        "pregunta": "20. What lifestyle modifications are recommended alongside pharmacologic treatment for prevention of glucocorticoid-induced osteoporosis?",
        "respuesta": "Lifestyle modifications recommended alongside pharmacologic treatment for prevention of glucocorticoid-induced osteoporosis include:\n\n- Adequate intake of calcium and vitamin D to support bone health  \n- Regular weight-bearing and muscle-strengthening exercises to improve bone density and reduce fall risk  \n- Avoidance of smoking and excessive alcohol consumption, both of which can worsen bone loss  \n- Fall prevention strategies to minimize fracture risk, such as home safety assessments and balance training  \n- Maintaining a healthy body weight to support skeletal strength  \n\nThese measures help enhance bone strength and reduce fracture risk in patients receiving glucocorticoids."
    }
]